검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Hydroxydaunomycin (Hydroxydaunomycin) Jiangsu HengRui Medicine Co., Ltd.·Richter Syndrome ORR 95%·t½ 78.4 days |
|---|---|
Overview Program | Hydroxydaunomycin |
Overview Company | Jiangsu HengRui Medicine Co., Ltd. |
Overview Modality | ADC |
Overview Target | Richter Syndrome |
Overview Indication | Richter Syndrome; Chronic Lymphocytic Leukemia |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted drug delivery system achieves safe and synergistic chemo-immunotherapy through homologous targeting-mediated pyroptosis and activation of the cGAS-STING pathway |
MoA Biomarker | biomarker for risk stratification and timely cardioprotective intervention |
PK/PD Half-life | 78.4 days |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Human, Mouse, Rat, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Human, Mouse, Rat, In vitro |
Toxicology Major finding | pneumonitis, were observed |
Clinical Primary efficacy | ORR 95% |
Clinical ORR | 95.0% |
Clinical Result source | ClinicalTrials.gov NCT03677141 |
Clinical Data Tier / Score | A · 62 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Hydroxydaunomycin (Hydroxydaunomycin) Jiangsu HengRui Medicine Co., Ltd.·Richter Syndrome ORR 95%·t½ 78.4 days |
|---|---|
Overview Program | Hydroxydaunomycin |
Overview Company | Jiangsu HengRui Medicine Co., Ltd. |
Overview Modality | ADC |
Overview Target | Richter Syndrome |
Overview Indication | Richter Syndrome; Chronic Lymphocytic Leukemia |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted drug delivery system achieves safe and synergistic chemo-immunotherapy through homologous targeting-mediated pyroptosis and activation of the cGAS-STING pathway |
MoA Biomarker | biomarker for risk stratification and timely cardioprotective intervention |
PK/PD Half-life | 78.4 days |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Human, Mouse, Rat, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Human, Mouse, Rat, In vitro |
Toxicology Major finding | pneumonitis, were observed |
Clinical Primary efficacy | ORR 95% |
Clinical ORR | 95.0% |
Clinical Result source | ClinicalTrials.gov NCT03677141 |
Clinical Data Tier / Score | A · 62 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교